| Name | Kif15-IN-2 |
|---|---|
| Synonyms |
3(2H)-Quinazolineacetamide, 1,4-dihydro-α-(1-methylethyl)-N-[4-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-thiazolyl]-2,4-dioxo-, (αS)-
(2S)-2-(2,4-Dioxo-1,4-dihydro-3(2H)-quinazolinyl)-3-methyl-N-[4-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1,3-thiazol-2-yl]butanamide |
| Description | Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases. |
|---|---|
| Related Catalog | |
| Target |
KIF15 |
| In Vitro | Kif15-IN-2 (Compound 14) is an inhibitor of the mitotic kinesin Hs Kif15, with the potential activities against cellular proliferative diseases such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C20H20N6O4S |
| Molecular Weight | 440.476 |
| Exact Mass | 440.126678 |
| LogP | 1.57 |
| Index of Refraction | 1.639 |
| Storage condition | 2-8℃ |